The role of microglia in antibody-mediated clearance of amyloid-beta from the brain

CNS and Neurological Disorders - Drug Targets

Volumn 8, Issue 1, 2009, Pages 7-15

  Morgan, Dave ^a  

^a UNIVERSITY OF SOUTH FLORIDA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN ANTIBODY; AMYLOID BETA PROTEIN[25-35]; CARBOXY TERMINAL AMYLOID BETA PROTEIN X 40 ANTIBODY FAB FRAGMENT; CD45 ANTIGEN; FC RECEPTOR; MINOCYCLINE; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY 2H6; MONOCLONAL ANTIBODY 6E10; UNCLASSIFIED DRUG; ANTIBODY;

ACTIVE IMMUNIZATION; ALZHEIMER DISEASE; ARTICLE; AUTOIMMUNE DISEASE; BRAIN HEMORRHAGE; CELL ACTIVATION; CEREBROVASCULAR DISEASE; DEGLYCOSYLATION; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; HUMAN; HYPOTHESIS; IMMUNOTHERAPY; INFLAMMATION; MEMORY; MICROGLIA; NONHUMAN; PHAGOCYTOSIS; PROTEIN AGGREGATION; PROTEIN BINDING; TREATMENT OUTCOME; ANIMAL; IMMUNOLOGY; METABOLISM; METHODOLOGY; MOUSE; REVIEW;

ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN; ANIMALS; ANTIBODIES; HUMANS; IMMUNOTHERAPY; MICE; MICROGLIA; PHAGOCYTOSIS;

EID: 65649098369     PISSN: 18715273     EISSN: None     Source Type: Journal    
DOI: 10.2174/187152709787601821     Document Type: Article

References (55)

1. Schenk, D.; Barbour, R.; Dunn, W.; Gordon, G.; Grajeda, H.; Guido, T.; Hu, K.; Huang, J.; Johnson-Wood, K.; Khan, K.; Kholodenko, D.; Lee, M.; Liao, Z.; Lieberburg, I.; Motter, R.; Mutter, L.; Soriano, F.; Shopp, G.; Vasquez, N.; Vandevert, C.; Walker, S.; Wogulis, M.; Yednock, T.; Games, D.; Seubert, P. Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature, 1999, 400, 173-177.
2. Solomon, B.; Koppel, R.; Frankel, D.; Hanan-Aharon, E. Disaggregation of Alzheimer beta-amyloid by site-directed mAb. Proc. Natl. Acad. Sci. USA, 1997, 94(8), 4109-4112.
3. Solomon, B.; Koppel, R.; Hanan, E.; Katzav, T. Monoclonal antibodies inhibit in vitro fibrillar aggregation of the Alzheimer beta-amyloid peptide. Proc. Natl. Acad. Sci. USA, 1996, 93(1), 452-455.
4. Morgan, D. Immunotherapy for Alzheimer's disease. J. Alzheimers Dis., 2006, 9(3 Suppl), 425-432.
5. Bard, F.; Cannon, C.; Barbour, R.; Burke, R.L.; Games, D.; Grajeda, H.; Guido, T.; Hu, K.; Huang, J.; Johnson-Wood, K.; Khan, K.; Kholodenko, D.; Lee, M.; Lieberburg, I.; Motter, R.; Nguyen, M.; Soriano, F.; Vasquez, N.; Weiss, K.; Welch, B.; Seubert, P.; Schenk, D.; Yednock, T. Peripherally administered antibodies against amyloid beta-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease. Nat. Med., 2000, 6(8), 916-919.
6. Webster, S.D.; Galvan, M.D.; Ferran, E.; Garzon-Rodriguez, W.; Glabe, C.G.; Tenner, A. J. Antibody-mediated phagocytosis of the amyloid beta-peptide in microglia is differentially modulated by C1q. J. Immunol., 2001, 166(12), 7496-7503.
7. Koenigsknecht-Talboo, J.; Landreth, G.E. Microglial phagocytosis induced by fibrillar beta-amyloid and IgGs are differentially regulated by proinflammatory cytokines. J. Neurosci., 2005, 25(36), 8240-8249.
8. Das, P.; Howard, V.; Loosbrock, N.; Dickson, D.; Murphy, M.P.; Golde, T.E. Amyloid-beta immunization effectively reduces amyloid deposition in FcRgamma-/- knock-out mice. J. Neurosci., 2003, 23(24), 8532-8538.
9. DeMattos, R.B.; Bales, K.R.; Cummins, D.J.; Dodart, J.C.; Paul, S.M.; Holtzman, D.M. Peripheral anti-A beta antibody alters CNS and plasma A beta clearance and decreases brain A beta burden in a mouse model of Alzheimer's disease. Proc. Natl. Acad. Sci. USA, 2001, 98(15), 8850-8855.
10. Deane, R.; Sagare, A.; Hamm, K.; Parisi, M.; LaRue, B.; Guo, H.; Wu, Z.; Holtzman, D.M.; Zlokovic, B. V. IgG-assisted age-dependent clearance of Alzheimer's amyloid beta peptide by the blood-brain barrier neonatal Fc receptor. J. Neurosci., 2005, 25(50), 11495-11503.
11. Akiyama, H.; Barger, S.; Barnum, S.; Bradt, B.; Bauer, J.; Cole, G.M.; Cooper, N.R.; Eikelenboom, P.; Emmerling, M.; Fiebich, B.L.; Finch, C.E.; Frautschy, S.; Griffin, W.S.; Hampel, H.; Hull, M.; Landreth, G.; Lue, L.; Mrak, R.; Mackenzie, I.R.; McGeer, P.L.; O'Banion, M. K.; Pachter, J.; Pasinetti, G.; Plata-Salaman, C.; Rogers, J.; Rydel, R.; Shen, Y.; Streit, W.; Strohmeyer, R.; Tooyoma, I.; Van Muiswinkel, F.L.; Veerhuis, R.; Walker, D.; Webster, S.; Wegrzyniak, B.; Wenk, G.; Wyss-Coray, T. Inflammation and Alzheimer's disease. Neurobiol. Aging, 2000, 21(3), 383-421.
12. Meda, L.; Cassatella, M.A.; Szendrei, G.I.; Otvos, L, Jr.; Baron, P.; Villalba, M.; Ferrari, D.; Rossi, F. Activation of microglial cells by beta-amyloid protein and interferon-gamma. Nature, 1995, 374(6523), 647-650.
13. Holcomb, L.A.; Gordon, M.N.; McGowan, E.; Yu, X.; Benkovic, S.; Jantzen, P.; Wright, K.; Saad, I.; Mueller, R.; Morgan, D.; Sanders, S.; Zehr, C.; O'Campo, K.; Hardy, J.; Prada, C.M.; Eckman, C.; Younkin, S.; Hsiao, K.; Duff, K. Accelerated Alzheimer-type phenotype in transgenic mice carrying both mutant amyloid precursor protein and presenilin 1 transgenes. Nat. Med., 1998, 4, 97-100.
14. Morgan, D.; Diamond, D.M.; Gottschall, P.E.; Ugen, K.E.; Dickey, C.; Hardy, J.; Duff, K.; Jantzen, P.; DiCarlo, G.; Wilcock, D.; Connor, K.; Hatcher, J.; Hope, C.; Gordon, M.; Arendash, G. W. A beta peptide vaccination prevents memory loss in an animal model of Alzheimer's disease. Nature, 2000, 408(6815), 982-985.
15. Herber, D.L.; Roth, L.M.; Wilson, D.; Wilson, N.; Mason, J.E.; Morgan, D.; Gordon, M.N. Time-dependent reduction in Abeta levels after intracranial LPS administration in APP transgenic mice. Exp. Neurol., 2004, 190(1), 245-253.
16. DiCarlo, G.; Wilcock, D.; Henderson, D.; Gordon, M.; Morgan, D. Intrahippocampal LPS injections reduce Aá load in APP+PS1 transgenic mice. Neurobiol. Aging, 2001, 22, 1007-1012.
17. Malm, T.M.; Koistinaho, M.; Parepalo, M.; Vatanen, T.; Ooka, A.; Karlsson, S.; Koistinaho, J. Bone-marrow-derived cells contribute to the recruitment of microglial cells in response to beta-amyloid deposition in APP/PS1 double transgenic Alzheimer mice. Neurobiol. Dis., 2005, 18(1), 134-142.
18. Quinn, J.; Montine, T.; Morrow, J.; Woodward, W.R.; Kulhanek, D.; Eckenstein, F. Inflammation and cerebral amyloidosis are disconnected in an animal model of Alzheimer's disease. J. Neuroimmunol., 2003, 137(1-2), 32-41.
19. Shaftel, S.S.; Kyrkanides, S.; Olschowka, J.A.; Miller, J.N.; Johnson, R.E.; O'Banion, M.K. Sustained hippocampal IL-1 beta overexpression mediates chronic neuroinflammation and ameliorates Alzheimer plaque pathology. J. Clin. Invest., 2007, 117(6), 1595-1604.
20. Frenkel, D.; Puckett, L.; Petrovic, S.; Xia, W.; Chen, G.; Vega, J.; Dembinsky-Vaknin, A.; Shen, J.; Plante, M.; Burt, D.S.; Weiner, H.L. A nasal proteosome adjuvant activates microglia and prevents amyloid deposition. Ann. Neurol., 2008, 63(5), 591-601.
21. Wyss-Coray, T.; Yan, F.; Lin, A.H.; Lambris, J.D.; Alexander, J.J.; Quigg, R.J.; Masliah, E. Prominent neurodegeneration and increased plaque formation in complement-inhibited Alzheimer's mice. Proc. Natl. Acad. Sci. USA, 2002, 99(16), 10837-10842.
22. Maier, M.; Peng, Y.; Jiang, L.; Seabrook, T.J.; Carroll, M.C.; Lemere, C.A. Complement C3 deficiency leads to accelerated amyloid beta plaque deposition and neurodegeneration and modulation of the microglia/ macrophage phenotype in amyloid precursor protein transgenic mice. J. Neurosci., 2008, 28(25), 6333-6341.
23. Morgan, D.; Gordon, M.N.; Tan, J.; Wilcock, D.; Rojiani, A.M. Dynamic complexity of the microglial activation response in transgenic models of amyloid deposition: implications for Alzheimer therapeutics. J. Neuropathol. Exp. Neurol., 2005, 64(9), 743-753.
24. Farfara, D.; Lifshitz, V.; Frenkel, D. Neuroprotective and neurotoxic properties of glial cells in the pathogenesis of Alzheimer's disease. J. Cell Mol. Med., 2008, 12(3), 762-780.
25. Rogers, J.; Mastroeni, D.; Leonard, B.; Joyce, J.; Grover, A. Neuroinflammation in Alzheimer's disease and Parkinson's disease: are microglia pathogenic in either disorder? Int. Rev. Neurobiol., 2007, 82, 235-246.
26. Wyss-Coray, T. Inflammation in Alzheimer disease: driving force, bystander or beneficial response? Nat. Med., 2006, 12(9), 1005-1015.
27. Colton, C.A.; Mott, R.T.; Sharpe, H.; Xu, Q.; Van Nostrand, W.E.; Vitek, M.P. Expression profiles for macrophage alternative activation genes in AD and in mouse models of AD. J. Neuroinflammation, 2006, 3, 27.
28. Wilcock, D.M.; DiCarlo, G.; Henderson, D.; Jackson, J.; Clarke, K.; Ugen, K.E.; Gordon, M.N.; Morgan, D. Intracranially administered anti-Abeta antibodies reduce beta-amyloid deposition by mechanisms both independent of and associated with microglial activation. J. Neurosci., 2003, 23(9), 3745-3751.
29. Wilcock, D.M.; Munireddy, S.K.; Rosenthal, A.; Ugen, K.E.; Gordon, M.N.; Morgan, D. Microglial activation facilitates Abeta plaque removal following intracranial anti-Abeta antibody administration. Neurobiol. Dis., 2004, 15(1), 11-20.
30. Bacskai, B.J.; Kajdasz, S.T.; McLellan, M.E.; Games, D.; Seubert, P.; Schenk, D.; Hyman, B.T. Non-Fcmediated mechanisms are involved in clearance of amyloid-beta in vivo by immunotherapy. J. Neurosci., 2002, 22(18), 7873-7878.
31. Garcia-Alloza, M.; Borrelli, L. A.; Rozkalne, A.; Hyman, B.T.; Bacskai, B. J. Curcumin labels amyloid pathology in vivo, disrupts existing plaques, and partially restores distorted neurites in an Alzheimer mouse model. J. Neurochem., 2007, 102(4), 1095-1104.
32. Strohmeyer, R.; Kovelowski, C.J.; Mastroeni, D.; Leonard, B.; Grover, A.; Rogers, J. Microglial responses to amyloid beta peptide opsonization and indomethacin treatment. J. Neuroinflammation, 2005, 2, 18.
33. Rebe, S.; Solomon, B. Deglycosylation of anti-beta amyloid antibodies inhibits microglia activation in BV-2 cellular model. Am. J. Alzheimers Dis. Demen., 2005, 20(5), 303-313.
34. Takata, K.; Hirata-Fukae, C.; Becker, A. G.; Chishiro, S.; Gray, A.J.; Nishitomi, K.; Franz, A.H.; Sakaguchi, G.; Kato, A.; Mattson, M.P.; Laferla, F.M.; Aisen, P.S.; Kitamura, Y.; Matsuoka, Y. Deglycosylated anti-amyloid beta antibodies reduce microglial phagocytosis and cytokine production while retaining the capacity to induce amyloid beta sequestration. Eur. J. Neurosci., 2007, 26(9), 2458-2565.
35. Carty, N.C.; Wilcock, D.M.; Rosenthal, A.; Grimm, J.; Pons, J.; Ronan, V.; Gottschall, P.E.; Gordon, M.N.; Morgan, D. Intracranial administration of deglycosylated C-terminal-specific anti-Abeta antibody efficiently clears amyloid plaques without activating microglia in amyloid-depositing transgenic mice. J. Neuroinflammation, 2006, 3(1), 11.
36. Pfeifer, M.; Boncristiano, S.; Bondolfi, L.; Stalder, A.; Deller, T.; Staufenbiel, M.; Mathews, P.M.; Jucker, M. Cerebral hemorrhage after passive anti-Abeta immunotherapy. Science, 2002, 298(5597), 1379.
37. Wilcock, D.M.; Rojiani, A.; Rosenthal, A.; Subbarao, S.; Freeman, M.J.; Gordon, M.N.; Morgan, D. Passive immunotherapy against Abeta in aged APP-transgenic mice reverses cognitive deficits and depletes parenchymal amyloid deposits in spite of increased vascular amyloid and microhemorrhage. J. Neuroinflammation, 2004, 1(1), 24.
38. Racke, M.M.; Boone, L.I.; Hepburn, D.L.; Parsadainian, M.; Bryan, M.T.; Ness, D.K.; Piroozi, K.S.; Jordan, W.H.; Brown, D.D.; Hoffman, W.P.; Holtzman, D.M.; Bales, K.R.; Gitter, B.D.; May, P.C.; Paul, S.M.; DeMattos, R.B. Exacerbation of cerebral amyloid angiopathy-associated microhemorrhage in amyloid precursor protein transgenic mice by immunotherapy is dependent on antibody recognition of deposited forms of amyloid beta. J. Neurosci., 2005, 25(3), 629-636.
39. Wilcock, D.M.; Jantzen, P.T.; Li, Q.; Morgan, D.; Gordon, M.N. Amyloid-beta vaccination, but not nitro-nonsteroidal anti-inflammatory drug treatment, increases vascular amyloid and microhemorrhage while both reduce parenchymal amyloid. Neuroscience, 2007, 144(3), 950-960.
40. Wilcock, D.M.; Alamed, J.; Gottschall, P.E.; Grimm, J.; Rosenthal, A.; Pons, J.; Ronan, V.; Symmonds, K.; Gordon, M. N.; Morgan, D. Deglycosylated antiamyloid-beta antibodies eliminate cognitive deficits and reduce parenchymal amyloid with minimal vascular consequences in aged amyloid precursor protein transgenic mice. J. Neurosci., 2006, 26(20), 5340-5346.
41. Schroeter, S.; Khan, K.; Barbour, R.; Doan, M.; Chen, M.; Guido, T.; Gill, D.; Basi, G.; Schenk, D.; Seubert, P.; Games, D. Immunotherapy reduces vascular amyloid-beta in PDAPP mice. J. Neurosci., 2008, 28(27), 6787-6793.
42. Orgogozo, J.M.; Gilman, S.; Dartigues, J.F.; Laurent, B.; Puel, M.; Kirby, L.C.; Jouanny, P.; Dubois, B.; Eisner, L.; Flitman, S.; Michel, B.F.; Boada, M.; Frank, A.; Hock, C. Subacute meningoencephalitis in a subset of patients with AD after Abeta42 immunization. Neurology, 2003, 61(1), 46-54.
43. Holmes, C.; Boche, D.; Wilkinson, D.; Yadegarfar, G.; Hopkins, V.; Bayer, A.; Jones, R.W.; Bullock, R.; Love, S.; Neal, J.W.; Zotova, E.; Nicoll, J.A. Longterm effects of Abeta42 immunisation in Alzheimer's disease: follow-up of a randomised, placebo-controlled phase I trial. Lancet, 2008, 372(9634), 216-223.
44. Boche, D.; Nicoll, J.A. The role of the immune system in clearance of Abeta from the brain. Brain Pathol., 2008, 18(2), 267-278.
45. Nicoll, J.A.; Barton, E.; Boche, D.; Neal, J. W.; Ferrer, I.; Thompson, P.; Vlachouli, C.; Wilkinson, D.; Bayer, A.; Games, D.; Seubert, P.; Schenk, D.; Holmes, C. Abeta species removal after abeta42 immunization. J. Neuropathol. Exp. Neurol., 2006, 65(11), 1040-1048.
46. Boche, D.; Zotova, E.; Weller, R.O.; Love, S.; Neal, J.W.; Pickering, R.M.; Wilkinson, D.; Holmes, C.; Nicoll, J.A. Consequence of A-beta immunization on the vasculature of human Alzheimer's disease brain. Brain, 2008, 131, 3299-3310.
47. Wilcock, D.M.; Rojiani, A.; Rosenthal, A.; Levkowitz, G.; Subbarao, S.; Alamed, J.; Wilson, D.; Wilson, N.; Freeman, M.J.; Gordon, M.N.; Morgan, D. Passive amyloid immunotherapy clears amyloid and transiently activates microglia in a transgenic mouse model of amyloid deposition. J. Neurosci., 2004, 24(27), 6144-6151.
48. DeKosky, S.T.; Harbaugh, R.E.; Schmitt, F.A.; Bakay, R.A.; Chui, H.C.; Knopman, D.S.; Reeder, T.M.; Shetter, A.G.; Senter, H.J.; Markesbery, W.R. Cortical biopsy in Alzheimer's disease: diagnostic accuracy and neurochemical, neuropathological, and cognitive correlations. Intraventricular Bethanecol Study Group. Ann. Neurol., 1992, 32, 625-632.
49. Morris, J.C.; Price, A.L. Pathologic correlates of nondemented aging, mild cognitive impairment, and early-stage Alzheimer's disease. J. Mol. Neurosci., 2001, 17(2), 101-118.
50. Gordon, M.N.; King, D.L.; Diamond, D.M.; Jantzen, P.T.; Boyett, K.L.; Hope, C.E.; Hatcher, J.M.; DiCarlo, G.; Gottschal, P.; Morgan, D.; Arendash, G.W. Correlation between cognitive deficits and Aá deposits in transgenic APP+PS1 mice. Neurobiol. Aging, 2001, 22, 377-385.
51. Streit, W.J. Microglia and Alzheimer's disease pathogenesis. J. Neurosci. Res., 2004, 77(1), 1-8.
52. Vasilevko, V.; Xu, F.; Previti, M.L.; Van Nostrand, W.E.; Cribbs, D.H. Experimental investigation of antibody-mediated clearance mechanisms of amyloid-beta in CNS of Tg-SwDI transgenic mice. J. Neurosci., 2007, 27(49), 13376-13383.
53. Thakker, D.; Weatherspoon, M.R.; Harrison, J.; Keene, T.E.; Lane, D.S.; Kaemmerer, W.F.; Stewart, G.R.; Shafer, L.L. Intracerebroventricular amyloid-β antibodies reduce cerebral amyloid angiopathy and associated microhemorrhages in aged Tg2576 transgenic mice. Proc. Natl. Acad. Sci. USA, 2009, in press.
54. Banks, W.A.; Terrell, B.; Farr, S.A.; Robinson, S.M.; Nonaka, N.; Morley, J.E. Passage of amyloid beta protein antibody across the blood-brain barrier in a mouse model of Alzheimer's disease. Peptides, 2002, 23(12), 2223-2226.
55. Karlnoski, R.A.; Rosenthal, A.; Alamed, J.; Ronan, V.; Gordon, M.N.; Gottschall, P.E.; Grimm, J.; Pons, J.; Morgan, D. Deglycosylated anti-Abeta antibody dose-response effects on pathology and memory in APP transgenic mice. J. Neuroimmune Pharmacol., 2008, 3(3), 187-197.